Bactiguard Holding AB (GB:0QV2)
LSE:0QV2
0QV2 Stock Chart & Stats
kr16.20
kr12.00(19.35%)
At close: 4:00 PM EST
kr16.20
kr12.00(19.35%)
Day’s Range― - ―
52-Week Rangekr15.25 - kr74.00
Previous CloseN/A
Volume0.00
Average Volume (3M)62.00
Market Cap
kr555.45M
Enterprise Valuekr669.14M
Total Cash (Recent Filing)kr35.34M
Total Debt (Recent Filing)kr161.30M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Jul 14, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding31,043,884
10 Day Avg. Volume0
30 Day Avg. Volume62
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)kr217.50M
Bulls Say, Bears Say
Bulls Say
Business Model — Licensing + Product SalesA dual revenue model combining technology licensing (royalties) and branded product sales provides durable, scalable income without full manufacturing exposure. Licensing lets Bactiguard monetize IP as partners scale, lowering capex needs and enabling margin expansion as royalty streams grow over time.
Differentiated IP: BIP Noble-metal CoatingProprietary BIP coating is a structural competitive advantage: a clearable, cross-device infection-prevention technology creates barriers to entry, supports licensing opportunities across catheters and tubes, and aligns with long-term hospital demand for device-level infection reduction.
Underlying Operating Capacity / Manageable LeveragePositive EBITDA and a balance sheet with moderate leverage (~0.5–0.7 D/E) imply the company can cover operating needs and fund growth without excessive financial strain. This combination supports execution of partnerships and product rollouts over the medium term.
Bears Say
Sustained UnprofitabilityOngoing negative EBIT and net income mean the company still consumes capital rather than generating returns. Persistent losses limit internal reinvestment, increase reliance on external financing, and keep ROE negative, constraining shareholder value creation over the medium term.
Declining Revenue TrendA falling top line and choppy revenue history reduce predictability of royalty and product sales growth. For a licensing-led model, sustained revenue declines undermine partner-driven royalties and make it harder to leverage fixed R&D and commercial costs into improved margins.
Inconsistent Cash Generation / Negative FCFVolatile cash flow with negative free cash flow raises refinancing and execution risk. Inconsistent FCF limits ability to invest in commercialization or sustain R&D without raising capital, potentially diluting shareholders or constraining long-term growth initiatives.
Bactiguard Holding AB News
0QV2 FAQ
What was Bactiguard Holding AB’s price range in the past 12 months?
Bactiguard Holding AB lowest share price was kr15.25 and its highest was kr74.00 in the past 12 months.
What is Bactiguard Holding AB’s market cap?
Bactiguard Holding AB’s market cap is kr555.45M.
When is Bactiguard Holding AB’s upcoming earnings report date?
Bactiguard Holding AB’s upcoming earnings report date is Jul 14, 2026 which is in 29 days.
How were Bactiguard Holding AB’s earnings last quarter?
Bactiguard Holding AB released its earnings results on Apr 23, 2026. The company reported -kr0.16 earnings per share for the quarter, missing the consensus estimate of -kr0.08 by -kr0.08.
Is Bactiguard Holding AB overvalued?
According to Wall Street analysts Bactiguard Holding AB’s price is currently Overvalued.
Does Bactiguard Holding AB pay dividends?
Bactiguard Holding AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of N/A. See more information on Bactiguard Holding AB dividends here
What is Bactiguard Holding AB’s EPS estimate?
Bactiguard Holding AB’s EPS estimate is -0.25.
How many shares outstanding does Bactiguard Holding AB have?
Bactiguard Holding AB has 31,043,884 shares outstanding.
What happened to Bactiguard Holding AB’s price movement after its last earnings report?
Bactiguard Holding AB reported an EPS of -kr0.16 in its last earnings report, missing expectations of -kr0.08. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bactiguard Holding AB?
Currently, no hedge funds are holding shares in GB:0QV2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bactiguard Holding AB
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.